Eisai

Oncology

Andree Amelsberg at ASCO 2024 and Jonah Comstock

ASCO 2024 - Andree Amelsberg

At ASCO 2024 last month, editor-in-chief Jonah Comstock caught up with Dr Andree Amelsberg, SVP of global and US medical affairs at Eisai, to chat about what the company was sharing at the

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

News

Leqembi maintenance dose filed in US, but SC form delayed

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio

ASCO 2024 - Andree Amelsberg

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

BMS hands back rights to cancer ADC licensed from Eisai

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Eisai, Biogen start delayed subcutaneous Leqembi filing

Leqembi maintenance dose filed in US, but SC form delayed

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eisai

Editor's Picks